Long-term safety and antiretroviral activity of hydroxyurea and didanosine in HIV-infected patients

Journal of Acquired Immune Deficiency Syndromes

Volumn 25, Issue 4, 2000, Pages 329-336

  Biron, François ^a,b   Ponceau, Bénédicte ^a,b   Bouhour, Damien ^a   Boibieux, André ^a   Verrier, Bernard ^b   Peyramond, Dominique ^a  

^a CROIX ROUSSE HOSPITAL   (France)

^b CNRS   (France)

Author keywords

Didanosine; HIV; Hydroxyurea; Long term efficacy; Toxicity

Indexed keywords

ANTIRETROVIRUS AGENT; DIDANOSINE; HYDROXYUREA;

ADULT; ANTIVIRAL ACTIVITY; ARTICLE; DRUG EFFECT; DRUG EFFICACY; DRUG SAFETY; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERAMYLASEMIA; HYPERURICEMIA; LYMPHOCYTE COUNT; LYMPHOCYTOPENIA; MAJOR CLINICAL STUDY; MALE; MOUTH ULCER; NEUTROPENIA; PRIORITY JOURNAL; RETROSPECTIVE STUDY; THROMBOCYTOPENIA; VIRUS LOAD;

EID: 0034490578     PISSN: 15254135     EISSN: None     Source Type: Journal    
DOI: 10.1097/00126334-200012010-00006     Document Type: Article

References (36)

1. Low levels of deoxynucleotides in peripheral blood lymphocytes: A strategy to inhibit human immunodeficiency virus type 1 replication
2. Hydroxyurea as an inhibitor of human immunodeficiency virus-type 1 replication
3. Anti-human immunodeficiency virus type 1 activity of hydroxyurea in combination with 2′,3′-dideoxynucleosides
4. Synergistic anti-human immunodeficiency virus type 1 effect of hydroxamate compounds with 2′,3′-dideoxyinosine in infected resting human lymphocytes
5. Intracellular activation of 2′,3′-dideoxyinosine and drug interactions in vitro
6. Long-term suppression of HIV-1 by hydroxyurea and didanosine
7. 1-year follow-up of the use of hydroxycarbamide and didanosine in HIV infection
8. Guidelines for the use of antiretroviral agents in HIV-infected adults adolescents
9. Antiretroviral therapy for HIV infection in 1998: Updated recommendations of the International AIDS Society-USA Panel
10. A placebo-controlled trial of didanosine plus stavudine, with and without hydroxyurea, for HIV infection. The Swiss HIV cohort Study
11. Quantifying residual HIV-1 replication in patients receiving combination antiretroviral therapy
12. Persistence of HIV-1 transcription in peripheral-blood mononuclear cells in patients receiving potent antiretroviral therapy
13. HIV-1 protease inhibitors. A review for clinicians
14. Clinical progression and virological failure on highly active antiretroviral therapy in HIV-1 patients: A prospective cohort study. Swiss HIV cohort study
15. Hydroxyurea toxicity combined with didanosine (ddI) in HIV-1-seropositive asymptomatic individuals
16. Combination of a drug targeting the cell with a drug targeting the virus controls human immunodeficiency virus type 1 resistance
17. Reducing T cell activation as a therapy for human immunodeficiency virus infection
18. Anti-CD4 therapy for AIDS suggested by mathematical models
19. Hydroxyurea and HIV: 5 years later-from antiviral to immune-modulating effects
20. + T lymphocyte subpopulations
21. Treatment of human immunodeficiency virus infection with hydroxyurea, didanosine and a protease inhibitor before seroconversion is associated with normalized immune parameters and limited viral reservoir
22. Hydroxyurea and didanosine long-term treatment prevents HIV breakthrough and normalizes immune parameters
23. Immune restoration by combination of a cytostatic drug (hydroxyurea) and anti-HIV drugs (didanosine and indinavir)
24. Hydroxyurea and didanosine is a more potent combination than hydroxyurea and zidovudine
25. A controlled trial of two nucleoside analogues plus indinavir in persons with human immunodeficiency virus infection and CD4 cell counts of 200 per cubic millimeter or less. AIDS clinical trials group 320 study team
26. Treatment with indinavir, zidovudine, and lamivudine in adults with human immunodeficiency virus infection and prior antiretroviral therapy
27. Hydroxyurea enhances the activities of didanosine, 9-[2-(phosphonylmethoxy)ethyl]adenine, and 9-[2-(phosphonylmethoxy)propyl]adenine against drug-susceptible and drug-resistant human immunodeficiency virus isolates